840490-23-5

Usage

Appearance

White crystalline solid

Usage

Organic synthesis and pharmaceutical research

Derivative

Imidazole (five-membered heterocyclic compound with a nitrogen atom)

Unique feature

Trifluoromethyl group on the fifth position of the imidazole ring

Chemical properties

Ability to act as a ligand in metal coordination complexes

Potential applications

Drug discovery and development of new therapeutic agents

Upstream product

• 55942-41-1 5-trifluoromethyl-3H-imidazole-4-carboxylic acid ethyl ester 

Downstream Products

• 1093256-51-9 N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-4-(trifluoromethyl)-1H-imidazole-5-carboxamide 
• 1414973-11-7 C₁₉H₁₀Cl₂F₄N₄O₂*C₂HF₃O₂ 

Relevant academic research and scientific papers

Substituted imidazole formate type derivative and application thereof

The invention discloses a compound shown as a formula I or a stereoisomer thereof or pharmaceutically acceptable salts thereof or a solvate thereof or a prodrug thereof or a metabolic product thereofor a deuterated derivative thereof. The compound is a substituted imidazole formate type derivative with a novel structure and belongs to the field of pharmaceutical chemistry. The invention further discloses application of the substituted imidazole formate type derivative to preparation of drugs with calming, hypnosis and/or anesthetic effects and application of the substituted imidazole formatetype derivative to preparation of drugs capable of controlling status epilepticus. The compound disclosed by the invention has a relatively good inhibition effect on a central nervous system and provides a new choice for clinically screening and/or preparing the drugs with the calming, hypnosis and/or anesthetic effects and capable of controlling the status epilepticus. The formula I is shown in the description.

Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase

A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.